Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Autophagy
    (4)
  • Apoptosis
    (3)
  • Akt
    (2)
  • EGFR
    (2)
  • HER
    (2)
  • PKA
    (2)
  • mTOR
    (2)
  • AMPK
    (1)
  • Antibacterial
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

bt474

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    19
    TargetMol | Inhibitors_Agonists
  • Natural Products
    2
    TargetMol | Natural_Products
PK11000
T445938275-34-2
PK11000 is a p53 targeting compound, has anti-tumor activities through activation of unstable p53.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
cct128930
T6303885499-61-6
CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM, 28-fold greater selectivity for Akt2 than the closely related PKA kinase.
  • Inquiry Price
4-6 weeks
Size
QTY
Lapatinib
GW572016, GSK572016
T0078231277-92-2
Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2 10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
  • Inquiry Price
Size
QTY
Buformin hydrochloride
NSC528218, NSC-528218, NSC 528218
T200291190-53-0
Buformin hydrochloride (NSC-528218) is a potent AMPK activator,an oral antidiabetic drug of the biguanide class. Buformin delays the absorption of glucose from the gastrointestinal tract increases insulin sensitivity and glucose uptake into cells and inhibits synthesis of glucose by the liver. Biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels.
  • Inquiry Price
Size
QTY
Neratinib
HKI-272
T2325698387-09-6
Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59 92 nM), respectively.
  • Inquiry Price
Size
QTY
Tanespimycin
NSC 330507, KOS 953, CP 127374, 17-AAG
T629075747-14-7
Tanespimycin (KOS 953) (17-AAG) is an inhibitor of Hsp90 that selectively inhibits BT474 tumor cell Hsp90 (IC50: 5 nM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
FT113
T79471630808-89-7
FT113 is a novel potent inhibitor of fatty acid synthase (fasn, IC50 : 213 nM),and exhibits anti-cancer activity
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
BTK-IN-38
T2012312758410-51-2
BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.
  • Inquiry Price
3-6 months
Size
QTY
BBO-10203
T2034282971769-60-3
BBO-10203 (Compound 758) binds to the RBD region of PI3Kα, hindering the interaction of K-, H-, and N-Ras with PI3Kα. It inhibits pAKT with an IC50 of less than 0.1 pM in BT474 cells.
  • Inquiry Price
Size
QTY
Timosaponin AIII
Timosaponin A3, Filiferin B, AneMarsaponin A3
T339541059-79-4
Timosaponin AIII (Timosaponin A3) induces autophagy in HeLa cells followed by apoptotic cell death (IC50: 10 μM). The Timosaponin AIII cellular response is mediated via inhibition of mTORC1 and induction of ER stress (IC50: 2.5 μM, BT474 cells; 6 μM, MDAMB231). The Timosaponin AIII pro-apoptotic response is selective for tumor cells over normal cells but autophagy is induced in both.
  • Inquiry Price
Size
QTY
p-SCN-Bn-HOPO
T341731822331-55-4
p-SCN-Bn-HOPO is an excellent bifunctional chelating agent for (89)Zr ImmunoPET, with low background, good tumor-organ contrast, and importantly, very low bone uptake for BT474 breast cancer imaging.
  • Inquiry Price
8-10 weeks
Size
QTY
CC260
T358742411088-26-9
CC260, a selective inhibitor for PI5P4Kα and PI5P4Kβ with Kis of 40 nM and 30 nM respectively, exhibits minimal to no inhibition against other protein kinases like Plk1 and RSK2. It is applicable in the research of cell energy metabolism, diabetes, and cancer[1].
  • Inquiry Price
6-8 weeks
Size
QTY
Furanodienone
T4S054424268-41-5
1. Furanodienone has effects on MCF-7 cells are mediated, at least in part, by inhibiting ERα signaling. 2. Furanodienone inhibits EGFR HER2 signaling pathway in BT474 and SKBR3 cells, the effect is specifically dependent on the expression of HER2 but not EGFR .
  • Inquiry Price
Size
QTY
CCT128930 hydrochloride
CCT128930 hydrochloride(885499-61-6 Free base)
T6303L2453324-32-6
CCT128930 hydrochloride (CCT128930 hydrochloride) is a potent and selective inhibitor of AKT with IC50 of 6 nM. CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC50: 168 nM) through the targeting of Met282 of AKT, as well as 20-fold selectivity over p70S6K (IC50: 120 nM).
  • Inquiry Price
Size
QTY
CNBCA
T79311
CNBCA, a selective and potent competitive inhibitor of the SHP2 enzyme, exhibits an IC50 value of 0.87 μM. It binds to the full-length SHP2, effectively inhibiting its enzyme activity, as well as impeding pAkt and pERK1 2. Furthermore, CNBCA suppresses the proliferation of BT474 and MDA-MB468 cells, indicating potential utility in breast cancer research [1].
  • Inquiry Price
Size
QTY
Fasnall benzenesulfonate
T853052187367-11-7
Fasnall, a fatty acid synthase (FASN) inhibitor, exhibits an IC50 of 3.71 μM against the human recombinant enzyme. It halts tritiated acetate incorporation into lipids (IC50= 5.84 μM), boosts ceramide levels, and triggers lipid droplet formation in BT474 HER2+ breast cancer cells. Demonstrating antiproliferative effects on various breast cancer cell lines, including non-tumorigenic MCF-10A and tumorigenic MCF-7, MDA-MB-468, BT474, and SK-BR-3, its efficacy is directly linked to FASN expression in vitro. In murine models of HER2+ breast cancer, particularly the MMTV-Neu model, Fasnall significantly reduces tumor volume and extends survival. Furthermore, it enhances the efficacy of carboplatin in vivo, bolstering the objective response rate of stable disease from 25% with carboplatin alone to 88% when paired with Fasnall.
  • Inquiry Price
8-10 weeks
Size
QTY
ZN-A-1041
T876752414056-31-6
ZN-A-1041 is an inhibitor of HER2 in BT474 cells with an IC50 of 9.5 nM and wt-EGFR in H838 cells with an IC50 of 12 μM. It can be utilized for cancer and inflammation research [1].
  • Inquiry Price
10-14 weeks
Size
QTY
HVH-2930
T886463034605-72-3
HVH-2930 is an inhibitor of Heat Shock Protein 90 (HSP90). It suppresses the cell viability of BT474 (Trastuzumab sensitive) and JIMT-1 (Trastuzumab resistant) by downregulating HSP90 client proteins such as HER2, p-HER2, AKT, p-AKT, cyclin D1, and survivin, with IC50 values of 6.86 μM and 4.42 μM, respectively. Additionally, HVH-2930 demonstrates antitumor efficacy in a mouse model and exhibits favorable pharmacokinetic properties in vivo.
  • Inquiry Price
10-14 weeks
Size
QTY
BAZ1A-IN-1
T9552941521-45-5
BAZ1A-IN-1 is a potent BAZ1A inhibitor with a KD value of 0.52 μM for the BAZ1A bromodomain, demonstrating strong anti-survival activity against cancer cell lines with high BAZ1A expression and weak or no activity against cancer cells with low BAZ1A expression.
  • Inquiry Price
Size
QTY